Kollidon VA64, a membrane-resealing agent, reduces histopathology and improves functional outcome after controlled cortical impact in mice

J Cereb Blood Flow Metab. 2012 Mar;32(3):515-24. doi: 10.1038/jcbfm.2011.158. Epub 2011 Nov 16.

Abstract

Loss of plasma membrane integrity is a feature of acute cellular injury/death in vitro and in vivo. Plasmalemma-resealing agents are protective in acute central nervous system injury models, but their ability to reseal cell membranes in vivo has not been reported. Using a mouse controlled cortical impact (CCI) model, we found that propidium iodide-positive (PI+) cells pulse labeled at 6, 24, or 48 hours maintained a degenerative phenotype and disappeared from the injured brain by 7 days, suggesting that plasmalemma permeability is a biomarker of fatal cellular injury after CCI. Intravenous or intracerebroventricular administration of Kollidon VA64, poloxamer P188, or polyethylene glycol 8000 resealed injured cell membranes in vivo (P<0.05 versus vehicle or poloxamer P407). Kollidon VA64 (1 mmol/L, 500 μL) administered intravenously to mice 1 hour after CCI significantly reduced acute cellular degeneration, chronic brain tissue damage, brain edema, blood-brain barrier damage, and postinjury motor deficits (all P<0.05 versus vehicle). However, VA64 did not rescue pulse-labeled PI+ cells from eventual demise. We conclude that PI permeability within 48 hours of CCI is a biomarker of eventual cell death/loss. Kollidon VA64 reduces secondary damage after CCI by mechanisms other than or in addition to resealing permeable cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / metabolism
  • Blood-Brain Barrier / pathology
  • Brain Injuries / pathology
  • Brain Injuries / physiopathology
  • Brain Injuries / prevention & control*
  • Cell Death / drug effects
  • Cell Membrane / drug effects*
  • Cell Membrane / pathology
  • Cell Membrane Permeability*
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / injuries
  • Cerebral Cortex / pathology*
  • Disease Models, Animal
  • Injections, Intravenous
  • Injections, Intraventricular
  • Magnetic Resonance Imaging
  • Male
  • Mice
  • Motor Activity / drug effects
  • Motor Activity / physiology
  • Pyrrolidines / administration & dosage
  • Pyrrolidines / therapeutic use*
  • Vinyl Compounds / administration & dosage
  • Vinyl Compounds / therapeutic use*

Substances

  • Pyrrolidines
  • Vinyl Compounds
  • poly(vinylpyrrolidone-co-vinyl-acetate)